NMCC Clinical Trials: Recruiting
The listing below of clinical trials in use by New Mexico Cancer Center is primarily intended for medical and radiation oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. Unless otherwise noted, the information below, including Trial Status, Date Opened and Date Updated, is obtained from ClinicalTrials.gov. Complete detailed information including eligibility criteria for each trial is available by clicking the ClinicalTrials.gov link provided in that trial's Description Box.
Please contact us here for trail details: research@nmohc.com
Clinical Trials
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents.
Name: TROPION_Breast05_D7630C0001
Name: PRL-02-1001: Propella Therapeutics
Description: "Multicenter" means the study is taking place at multiple locations. This study is testing a new injectable medication called PRL-02 for men with advanced prostate cancer.
Name: PRESERVE-006: OncoC4, Inc.
Description: This study is testing a new combination treatment for men with advanced prostate cancer that has spread to the bones (mCRPC).
Name: EMBER-4_J2J-MC-JZLH_Eli Lilly and Company
Description: This study is comparing two medications for people with early-stage breast cancer that is estrogen-receptor positive (ER+) and HER2-negative (HER2-).
Name: DORA Radium-223 Memorial Sloan Kettering
Description: This study is testing a new combination treatment for men with prostate cancer that has spread to the bones.
Name: CTP-SCC-03: Alpha Tau Medical LTD.
Description: This study is testing a new treatment option (Alpha DaRT224) for people with skin cancer that has come back (recurrent cutaneous squamous cell carcinoma).
Name: CAMBRIA-2_D8535C00001: AstraZeneca
Description: This study is testing a new medication called Camizestrant (AZD9833) for people with early-stage breast cancer.
Name: Billion ToOne Northstar Response Clinical Validation Study NS-002
Description: This study is looking to improve a test (NorthStar Response assay) used to see how well cancer treatments are working.
Name: BEGIN Boston Gene BGER 001
Description: This is a research study looking at the benefits of advanced genetic testing for people with advanced cancer.
Name: BB-1701-G000-205: Elsai Inc.
Description: This study is for people with HER2-positive or HER2-low breast cancer that has spread to other parts of the body (unresectable or metastatic).
Name: TROPION Breasl03 D926XC00001: AstraZeneca
Description: TROPION-Breast3 stands for Triple Negative Breast Cancer Cisplatin nab-paclitaxel Durvalumab Versus Investigator's Choice. This study is looking at new treatment options for women with a specific type of breast cancer that has not completely responded to initial treatment (neoadjuvant therapy).